60 Degrees Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Geoffrey Dow

İcra Kurulu Başkanı

US$727.8k

Toplam tazminat

CEO maaş yüzdesi	34.35%
CEO görev süresi	4yrs
CEO sahipliği	0.7%
Yönetim ortalama görev süresi	3.4yrs
Yönetim Kurulu ortalama görev süresi	2.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Geoffrey Dow'un ücretlendirmesi 60 Degrees Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2026	n/a	n/a	-US$8m
Dec 31 2025	US$728k	US$250k	-US$8m
Sep 30 2025	n/a	n/a	-US$8m
Jun 30 2025	n/a	n/a	-US$8m
Mar 31 2025	n/a	n/a	-US$11m
Dec 31 2024	US$323k	US$228k	-US$8m
Sep 30 2024	n/a	n/a	-US$8m
Jun 30 2024	n/a	n/a	-US$2m
Mar 31 2024	n/a	n/a	-US$1m
Dec 31 2023	US$126k	US$126k	-US$4m
Sep 30 2023	n/a	n/a	-US$4m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$55k	US$55k	-US$6m
Sep 30 2022	n/a	n/a	-US$6m
Dec 31 2021	US$520k	US$520k	-US$4m
Dec 31 2020	US$283k	US$283k	-US$3m

Tazminat ve Piyasa: Geoffrey 'ın toplam tazminatı ($USD 727.75K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 641.77K ).

Tazminat ve Kazançlar: Geoffrey şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Geoffrey Dow (52 yo)

4yrs

Görev süresi

US$727,750

Tazminat

Dr. Geoffrey Stuart Dow, PH.D. serves as President, Chief Executive Officer and Director at 60 Degrees Pharmaceuticals, Inc. since June 1, 2022. Dr. Dow is Chairman, President and CEO of 60° Pharmaceutical...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Geoffrey Dow	Chairman	no data	US$727.75k	0.66% $ 25.1k
Tyrone Miller	CFO & Treasurer	3.4yrs	US$283.25k	0.050% $ 1.9k
Kristen Landon	Chief Commercial Officer	2.3yrs	US$311.79k	0.043% $ 1.6k
Bryan Smith	Chief Medical Officer	10.4yrs	Veri yok	Veri yok

3.4yrs

Ortalama Görev Süresi

55.5yo

Ortalama Yaş

Deneyimli Yönetim: SXTP 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Geoffrey Dow	Chairman	4yrs	US$727.75k	0.66% $ 25.1k
Charles Allen	Independent Director	2.9yrs	US$61.24k	0.0022% $ 83.8
Stephen Toovey	Independent Director	2.9yrs	US$58.24k	0.0022% $ 83.8
Eric Francois	Director	less than a year	Veri yok	Veri yok
Paul Field	Independent Director	2.9yrs	US$58.24k	0.0022% $ 83.8
Cheryl Xu	Director	2.9yrs	US$53.24k	0.15% $ 5.6k

2.9yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SXTP 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.9 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/06/08 16:35
Gün Sonu Hisse Fiyatı	2026/06/05 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

60 Degrees Pharmaceuticals, Inc. 2 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Lucas Ward	Ascendiant Capital Markets LLC
Matthew Keller	H.C. Wainwright & Co.

60 Degrees Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new and inexperienced directors

60 Degrees Pharmaceuticals, Inc., Annual General Meeting, Oct 08, 2025

Chairman recently bought US$90k worth of stock

60 Degrees Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

High number of new and inexperienced directors

First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates upgraded to US$6.01 loss, revenue downgraded

Price target increased by 33% to US$24.00

Consensus EPS estimates fall by 28%

Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

60 Degrees Pharmaceuticals Receives Written Notice from the Nasdaq

New major risk - Share price stability

60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24% of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study At NC State

60 Degrees Pharmaceuticals, Inc. Announces Clinical Site Now Open for Patient Enrollment for the B-Free Chronic Babesiosis Study At Mount Sinai Icahn School of Medicine

New major risk - Financial position

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

60 Degrees Pharmaceuticals, Inc. Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

60 Degrees Pharmaceuticals, Inc. Unveils Name of Chronic Babesiosis Clinical Trial: B-Free Chronic Babesiosis Study

60 Degrees Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.397532 million.

Consensus revenue estimates decrease by 35%, EPS upgraded

New major risk - Revenue and earnings growth

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

60 Degrees Pharmaceuticals, Inc., Annual General Meeting, Oct 08, 2025

Second quarter 2025 earnings: EPS in line with expectations, revenues disappoint

60 Degrees Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

60 Degrees Pharmaceuticals, Inc. to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

60 Degrees Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of Arakoda®? (Tafenoquine)8-Count Bottle Format

60 Degrees Pharmaceuticals, Inc. Announces Results of an Insurance Claims Analysis Related to Babesiosis and Chronic Fatum

First quarter 2025 earnings released

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 74%

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

Consensus revenue estimates increase by 10%

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

60 Degrees Pharmaceuticals, Inc. to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quality of KODATEF

60 Degrees Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.075003 million.

60 Degrees Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.043002 million.

60 Degrees Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.043002 million.

60 Degrees Pharmaceuticals, Inc. Announces the Approval of an Investigational Review Board Commissioned Phase II Clinical Study

60 Degrees Pharmaceuticals, Inc. Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. Microti) Babesiosis

Chairman recently bought US$90k worth of stock

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

60 Degrees Pharmaceuticals Inc. Announces ARAKODA Promotional Pilot in Advance of Expanded U.S. Launch

60 Degrees Pharmaceuticals, Inc. announced that it expects to receive $4 million in funding

60 Degrees Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$4.68 loss

60 Degrees Pharmaceuticals, Inc. Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

60 Degrees Pharmaceuticals Announces 1:12 Reverse Stock Split to Bring the Company into Compliance with the Nasdaq's $1.00 Minimum Bid Price Requirement for Maintaining its Nasdaq Listing

New major risk - Share price stability

60 Degrees Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.253603 million.

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia Microti Despite Prior Treatment

60 Degrees Pharmaceuticals, Inc. Announces First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center

60 Degrees Pharmaceuticals, Inc. Enters into an Agreement with Tufts Medical Center in Boston to Conduct the First Clinical Trial of Tafenoquine in Treating Human Babesiosis Patients

Consensus revenue estimates fall by 13%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

60 Degrees Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2024

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

60 Degrees Pharmaceuticals Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

High number of new and inexperienced directors

60 Degrees Pharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $2.4001 million.

60 Degrees Pharmaceuticals, Inc. Plans Pivotal Babesiosis Study with Tafenoquine

60 Degrees Pharmaceuticals, Inc. Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

60 Degrees Pharmaceuticals, Inc. announced delayed 10-Q filing

60 Degrees Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Required for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases

60 Degrees Pharmaceuticals, Inc.'s Subsidiary 60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements